瑞士CMA Microdialysis AB  www.microdialysis.se
CMA（全名CMA/MICRODIALYSIS)成立于1984年，是一家以研究為導(dǎo)向的高科技公司。總部設(shè)于瑞典斯德哥哥爾摩。其創(chuàng)辦人為瑞典著名的KAROLINSKA學(xué)院藥理大師URBAN UNGERSTEDT教授。由其公司的名字，可以了解到CMA公司的主要產(chǎn)品為微透析設(shè)備-一種最新的生物采樣技術(shù)，可用于麻醉或清醒的生物上。對(duì)醫(yī)學(xué)、藥學(xué)、生命科學(xué)等領(lǐng)域，提供嶄新的技術(shù)的發(fā)展空間，目前以此技術(shù)發(fā)展的論文已有千篇以上。
微透析（Microdialysis) 
是一種從生物活體內(nèi)進(jìn)行動(dòng)態(tài)微量生化取樣的新技術(shù)。具有活體取樣，動(dòng)態(tài)觀察，定量分析，采樣量小，組織損傷輕等特點(diǎn)。在神經(jīng)科學(xué)，醫(yī)藥研究等領(lǐng)域已獲得越來越廣泛的應(yīng)用。CMA微透析系統(tǒng)以其優(yōu)良的品質(zhì)，在業(yè)界享有很高的聲譽(yù)。CMA探針以其專利設(shè)計(jì)的精密結(jié)構(gòu)，模仿毛細(xì)血管，可以進(jìn)行高效率的活體取樣。
主要原理為將一種具有透析作用的微細(xì)探針置于采樣的生物組織內(nèi)，利用一部非常精細(xì)的注射泵，推送溶液至探針處，以達(dá)到與組織內(nèi)欲取出測(cè)量的低分子量或高分子量物質(zhì)，進(jìn)行透析交換，再將透析液做進(jìn)一步的分析。

Vision statement: "Microdialysis based research and diagnostics leads to a higher quality of life"
 
The Company
CMA Microdialysis is a Swedish medical device company devoted to the development, manufacturing and marketing of the Microdialysis technique. The company was formed in 1984 as the first company in the world to market Microdialysis products and know-how. Instruments, consumables and computer software are sold globally to universities, hospitals and pharmaceutical companies as unique tools for in vivo sampling and monitoring of organs and tissues.
CMA is the leading company developing and marketing Microdialysis products for the scientific & medical research field. Since 1994, CMA also offers unique Microdialysis products for clinical research and diagnostics. The products are produced in Sweden under ISO 13485 and according to FDA standards. With a highly specialized and skilled staff, consumables are manufactures in a Class 8 clean room environment. The head office is located outside Stockholm, Sweden, with subsidiaries in Germany and USA. CMA has distributors across the globe, responsible for local sales, service and support.
CMA is a subsidiary of Skanditek Industriförvaltning AB, a Swedish industrial holding company listed on the Stockholm Stock Exchange.
For a 6-minute overview of CMA Microdialysis and the opportunities with Clinical Microdialysis, click here
History
The concept of Microdialysis was born in the early 1970's. While examining the cross-section of a blood vessel among fluorescent nerve endings, Professor Urban Ungerstedt of the Karolinska Institute in Stockholm had the idea of using a dialysis tube as "an artificial blood capillary", in order to monitor chemical events in the tissue, see Microdialysis technique. The first paper on Microdialysis was published in 1974. Since then, over 12.000 scientific papers have been published on the technique - among them some 2.000 clinical investigations.
 
Some words from the CEO
CMA have for over 20 years developed, produced and marketed unique Microdialysis products and solutions. With customers in over 60 countries our policy is to develop and produce Microdialysis products that satisfy the highest customer and quality demands. We set the industry standards!
CMA's core competence lies in tissue chemistry and our extensive R&D efforts strive to continuously develop new products and solutions that contribute to a higher quality of life.
CMA has tight collaborations with leading research institutes and clinics, which is a prerequisite for successful product development and launch.
Following many years of intense research, I'm now excited to see that Microdialysis is breaking through as a diagnostic tool in clinical care. Our mission continues to be the leading provider of superior tools for metabolic research and diagnostics that offer clear benefits to patients and the healthcare industry.
If you have any ideas or comments, please don't hesitate to contact me.
Philip Siberg
CEO
philip.siberg@microdialysis.se
 
Products
CMA develops and produces complete range of Microdialysis products for basic research, clinical research and clinical diagnostics. The basic research portfolio includes a broad range of probes, pumps, fraction collectors, analyzers and complete systems for demanding research.
The clinical product range includes catheters and analyzers approved for human use. The system is used for monitoring the human brain, subcutaneous and intra-muscular use and continuous monitoring and detection of local changes in metabolism following gastrointestinal and hepatic surgery.
Intravenous Microdialysis offers novel opportunities for continuous monitoring of small substances in blood. By using an optimized membrane, CMA catheters can be implanted into peripheral veins up to 3 days, with very high accuracy.
The massive amount of data generated by Microdialysis and other complementary techniques can be analyzed by CMA's extraordinary computer software LABpilot and ICUpilot. They introduce the new concept of "Data Navigation" where data can be displayed and manipulated in a graphic environment. ICUpilot enables the complete bedside integration of all physiological, chemical and pharmacological data as unparalleled decision support for the medical professional.

Applications
As global drug development costs continue to escalate, partially because of the high attrition rate of development candidates, there is increasing pressure to improve the predictability of clinical outcomes from preclinical studies.
By understanding the exposure in the appropriate biophase, as well as the effect of a drug candidate at the site of action, selection and optimal doses of the best compound can be improved. Microdialysis is a practical and data-rich in vivo method, which is extremely useful tool to investigate the PK/PD profiles of drug candidates.
CMA’s basic research solutions are used by leading pharmaceutical companies in the drug discovery process to assess drug concentrations at the site of drug delivery.
In the clinic, Microdialysis is used to address various issues in different clinical fields, such as monitoring for early detection of secondary brain injuries, flap thrombosis, transplant rejection and anastomosis leakage. Microdialysis is also used in clinical pharmacology to measure target site concentrations of antibiotics or anticancer drugs in different tissues and organs and to subsequently relate target site PK to PD.
CMA’s clinical solutions are used by leading university hospitals around the globe for continuous tissue monitoring in the ICU.